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Background. ZTI-01 (fosfomycin, FOS, for injection) is currently under US 
development to treat complicated urinary tract infections. ZTI-01 is unique com-
pared with other antimicrobials in that it inhibits an early step in cell wall synthesis via 
covalent binding to MurA. ZTI-01 demonstrates broad in vitro activity against Gram-
negative (GN) and -positive (GP) bacteria, including multidrug-resistant (MDR) 
organisms. Our study goals were to determine the efficacy of ZTI-01 as a monotherapy 
or in combination with meropenem against MDR Pseudomonas aeruginosa in a pre-
clinical model of pulmonary infection.
Methods. 8 week old neutropenic mice were infected with a MDR strain of 
P. aeruginosa via intubation-mediated intratracheal (IMIT) instillation. 3 hours after 
instillation, mice received treatment with ZTI-01, meropenem, or ZTI-01 plus mero-
penem (combination therapy) q8h for 5 days. Mice were monitored every 8 hours for 
7 days for development of disease and moribund animals were humanely euthanized. 
Lungs and spleens were harvested at euthanasia, or at 7 days for survivors, and pro-
cessed for bacterial enumeration and development of pathology.
Results. Mice were challenged with a lethal dose of P. aeruginosa UNC-D. Mock 
treated animals succumbed to infection within 36 hours post-infection. Animals that 
received 6 g/kg/day ZTI-01 showed an increase in the MTD (52 hours) and 25% of 
the cohort were protected from lethal disease. Combining ZTI-01 with meropenem 
resulted in a significant increase in survival (≥75% of cohorts survived infection). 
Combination therapy also significantly decreased bacterial numbers in the lungs and 
inhibited dissemination to the spleens. Furthermore, animals receiving combination 
therapy were protected from significant inflammation in the lungs and the develop-
ment of pneumonia.
Conclusion. Here we report that combination therapy with ZTI-01 and merope-
nem provides significant improvements in all disease manifestations over treatment 
with each drug individually in a preclinical model for pulmonary infection with MDR 
P. aeruginosa. These data strongly support further evaluation of ZTI-01 in combination 
with other antibiotics as potential therapies against pulmonary infections with MDR 
bacteria.
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Background. The first case of an invasive infection caused by C. auris was reported 
in July of 2016. Multiple cases have since been reported with high mortality rates due 
to the multidrug-resistant nature of C. auris. Although C. auris shows increased sus-
ceptibility to the echinocandin class of antifungals, the use of these drugs is restricted 
to multiple IV administrations. CD101 is a novel echinocandin with enhanced stabil-
ity and pharmacokinetics, allowing for once weekly high dose administration. In this 
study, we evaluated the efficacy of CD101 in the treatment of disseminated C. auris 
infection using a murine model of disseminated candidiasis.
Methods. Female 6–8 week old CD-1 mice were immunosuppressed with cyclo-
phosphamide (200 mg/kg) 3 days prior to infection and 150 mg/kg 1 day post-infec-
tion. On the day of infection, mice were inoculated with 3 x 107 C. auris blastospores 
via the lateral tail vein. Mice were randomized into 5 groups (n = 5 for colony forming 
units (CFU) and n = 10 for survival): CD101 20 mg/kg administered by intraperitoneal 
(IP) injection, fluconazole 20 mg/kg administered per os (PO), amphotericin B 0.3 mg/
kg IP, and a vehicle control. Treatments were administered 2 hours post-infection (day 
1) and again on day 4 of the study for a total of 2 doses. Mice were monitored daily and 
a survival curve was generated. CFU groups were sacrificed on day 8 of the study. One 
kidney was removed from each mouse, homogenized, plated on potato dextrose agar 
(PDA), and incubated at 35°C for 2 days to determine CFU. The remaining survival 
mice were monitored until the end of the study (day 14).
Results. CD101 showed an average 3 log reduction in kidney CFU compared with 
fluconazole, amphotericin B, and vehicle treated groups, which was statistically signifi-
cant (P = 0.03, 0.03, and 0.04, respectively). At the end of the study, percent survival of 
mice in CD101, fluconazole, amphotericin B, vehicle, and untreated groups was 80, 0, 
30, 20, and 0%, respectively (Figure 1).
Conclusion. Taken together, our findings show that CD101 possesses potent 
antifungal activity against C. auris infection in a disseminated model of candidiasis. 
Additionally, treatment with CD101 resulted in a significantly higher overall percent 
survival. Further investigation of this drug is warranted.
Figure 1. Survival curve of mice in all treatment groups after 14 days.
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Background. Innate immune responses contribute to successful resolution 
of bacterial pneumonia. Bolstering host defense with immunomodulators might be 
increasingly needed to improve outcomes in antibiotic-resistant infections. One 
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candidate molecule is recombinant human plasma gelsolin (rhu-pGSN), an abun-
dant normal blood protein whose levels fall proportionally with disease severity. 
Pretreatment with rhu-pGSN has beneficial effects in many pre-clinical models of 
inflammation and injury, including pneumonia. We evaluated the effects of delaying 
therapy with rhu-pGSN up to 48 hours after lethal intra-nasal pneumococcal challenge 
in a mouse model to more closely mimic realistic clinical circumstances.
Methods. Adult Bl/6 mice were inoculated intra-nasally with S. pneumoniae sero-
type 3 on day 0, followed by subcutaneous rhu-pGSN 24 hours later for evaluation of 
bacterial clearance in lavage fluids. To assess effects on survival, rhu-pGSN was admin-
istered on days 2 and 3 after infection and effects monitored for 10 days. No antibiotics 
or other interventions were given.
Results. Treatment with rhu-pGSN at 24 hours after infection improved bacter-
ial clearance, seen as reduction of bacterial CFU in bronchoalveolar lavage fluid at 48 
hours (% of initial inoculum, vehicle vs.. rhu-pGSN (dose range 0.5–2 mg): 30 ± 13 
vs. 11 ± 7, n = 6 trials using inocula ranging 0.3–1.8 x 106 CFU, 3 mice/group/trial, 
P = .001). In 3 separate trials, pGSN (0.5 mg s.c.) reduced weight loss and mortality 
(%  survival, vehicle vs. pGSN: 40 vs. 80, 0 vs. 25, 17 vs. 43; n ≥ 16/group, P =.02). 
Increasing the dose to 1 mg further improved survival from 17 to 71%.
Conclusion. Rhu-pGSN can substantially improve survival in a murine model 
of fatal pneumococcal pneumonia, even when administered as single doses on days 2 
and 3 after infection without antibiotics. The data support further evaluation of pGSN 
as adjunctive therapy for serious infections with diverse pathogens and in models of 
antibiotic-resistant pneumonia.
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Background. Cefiderocol (S-649266) is a novel siderophore cephalosporin under 
development by Shionogi (Osaka, Japan). Previous studies have demonstrated cefider-
ocol efficacy against a diverse population of Gram-negative bacteria with MICs ≤ 4 μg/
mL. Our aim was to further define the agent’s clinical role by comparing the efficacy 
of humanized regimens of cefiderocol, FEP, and MEM against a subset of these Gram-
negative isolates.
Methods. 15 Gram-negative isolates were studied. MICs were determined by broth 
microdilution in triplicate, using reference CLSI methods. Pharmacokinetic studies were 
conducted to reproduce the humanized exposures of cefiderocol 2g q8h (3h inf.), FEP 
2g q8h (3h inf.), and MEM 2g q8h (3 hours inf.). Antibiotics were started 2h post thigh 
inoculation (0h) and continued for 24 hours in immunocompromised mice. Efficacy was 
determined as the change in log10CFU at 24h compared with 0 hour controls.
Results. 8 Enterobacteriaceae, 4 A. baumannii, and 3 P. aeruginosa isolates were 
studied. Cefiderocol, FEP, and MEM MICs were in the range of 0.12 to 8 μg/mL, ≤0.03 
to >64 μg/mL, and ≤0.06 to >64 μg/mL, respectively. Three of the 15 isolates were sus-
ceptible to both meropenem and cefepime. All remaining isolates demonstrated in 
vitro resistance to one or both comparator agents. Cefiderocol was efficacious against 
all 15 isolates, regardless of FEP or MEM resistance, producing bacterial reductions 
from 0 hour between 0.89 to 3.04 log10 CFU. Against FEP and MEM susceptible iso-
lates, cefiderocol treatment resulted in bacterial kill of 2.6 ± 0.5 and 2.1 ± 0.9 log10 CFU, 
respectively, similar to that of FEP (2.6 ± 0.5) and MEM (2.2 ± 0.6). Against MEM 
and FEP resistant isolates, cefiderocol produced a mean (± SD) bacterial reduction of 
1.5 ± 0.4 log10 CFU at 24 hours.
Conclusion. Cefiderocol humanized exposures produced antibacterial efficacy 
similar to MEM and FEP for susceptible pathogens, while also displaying activity 
against Enterobacteriaceae, A. baumannii, and P. aeruginosa with phenotypic resist-
ance to the comparator β-lactams. These studies support the potential clinical utility of 
cefiderocol against these difficult-to-treat multidrug-resistant pathogens.
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Background. Mucormycosis is a life-threatening infection with high mortality 
that occurs predominantly in immunocompromised patients. APX001A is an antifun-
gal agent that targets Gwt1, an early step in the conserved glycosylphosphotidyl inositol 
(GPI) post-translational modification pathway of surface proteins in eukaryotic cells. 
Inhibition of inositol acylation by APX001A results in pleiotropic effects such as inhi-
bition of maturation of GPI-anchored proteins necessary for growth and virulence and 
results in lethality. APX001A has in vitro activity against Mucorales. Here we assessed 
the in vivo activity of APX001A against Rhizopus delemar (MIC = 0.25 µg/mL).
Methods. ICR mice were immunosuppressed with cyclophosphamide (200 mg/kg) 
and cortisone acetate (500 mg/kg) on days -2, +3, and +8 relative to intratracheal infec-
tion with 2.5 x 105 cells of R.  delemar 99–880. For survival studies, treatment with 
APX001 (prodrug) at 52, 104, or 156 mg/kg (twice daily, po), was compared with lipo-
somal amphotericin B (LAmB) at 15 mg/kg (once daily, iv). Treatment started on day 
+1 through day +8 for APX001 and through day +4 for LAmB. Placebo mice received 
vehicle control. For fungal burden studies, dosing started 8 hours post infection through 
day +3. Mice were sacrificed on day +4. Survival time, and tissue fungal burden (by 
qPCR) served as efficacy endpoints.
Results. APX001 treatment at either 52 or 104  mg/kg prolonged survival of 
mice vs. placebo (n = 20 per arm) (21-day survival of 0% for placebo, 30% for 
52 mg/kg, 45% for 104 mg/kg, P < 0.05 by Log Rank test). APX001 at 104 mg/kg was 
as good as LAmB treatment (21-day survival of LAmB-treated mice [n = 20] =50%). 
APX001 at 156  mg/kg did not enhance survival vs. placebo. Further, APX001 at 
104 mg/kg and LAmB reduced pulmonary and brain fungal burden by ~1 log and 
1.5 log vs. placebo, respectively (P < 0.05, by Wilcoxon rank-sum). The 52 and 
the 156 mg/kg APX001 doses also reduced tissue fungal burden vs. placebo mice 
(0.5–1.0 log).
Conclusion. APX001 protected immunosuppressed mice from R. delemar infec-
tion with efficacy similar to that of LAmB. Higher doses of APX001 were not protective 
despite lowering fungal burden. Continued investigation of APX001 as a novel antifun-
gal agent against mucormycosis is warranted.
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Background. Bacterial cytological profiling accelerates drug discovery efforts 
by determining the mechanism of action (MOA) of newly developed antibacterial 
agents. Our goal was to adapt this technology to the identification and study of the 
MOA of antifungal compounds. Here we explore the utility of Fungal Cytological 
Profiling (FCP) of C.  albicans in revealing changes in morphology over time using 
for 6 antifungal agents with unique MOA using fluorescently labeled compounds that 
specifically stain a variety of subcellular structures including DNA and membranes. 
Included in the analysis was the novel broad spectrum Gwt1 inhibitor APX001A, the 
active moiety of the prodrug APX001 which is currently in clinical trials for invasive 
fungal infections.
Methods. The MICs of 6 antifungals vs. C.  albicans were determined by CLSI 
methodology. For FCP, antifungals were added to cultures (1 × 105 cells/mL) in RPMI 
1640 (buffered with MOPS) at concentrations near MIC: APX001A (0.064  µg/mL); 
caspofungin (1 µg/mL); fluconazole (2 µg/mL); flucytosine (2 µg/mL); amphotericin B 
(1 µg/mL) and nikkomycin (3.33 µg/mL) incubated at 35°C with shaking. At 4 hours 
and 24 hours, treated cultures were stained with various dyes (for 15 minutes), and 
staining examined under the fluorescence microscope. Dyes included FM 4–64 (mem-
branes), DAPI (DNA), and Sytox Green (cell viability). High-resolution fluorescence 
microscopy, image analysis and quantitation of cytological parameters (cell length, 
width, shape, DNA content) were used to create a cytological profile for each growth 
condition.
